title: A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.
abstract: Tamoxifen (TAM) has been reported to enhance cisplatin (CDDP) cytotoxicity in experimental and clinical melanoma studies. Based on our previous experience with sequential cisplatin-interleukin-2 (IL2)-interferon (IFN), we performed a phase II study of TAM combined with our original CDDP-IL2-IFN regimen in 22 pretreated metastatic melanoma patients. With a 41% response rate (95% CI, 21-61) we confirmed the interesting antitumor activity of CDDP-IL2-IFN combination; however, TAM enhanced neither the response rate nor the duration of response, but appeared to induce significantly more myelotoxicity, as compared to our previous results with CDDP-IL2-IFN alone. Whereas mechanisms by which TAM may modulate CDDP cytotoxicity in melanoma tumors remain unknown, the exact place of TAM, if any, and its safety in chemotherapeutic or chemoimmunotherapeutic combinations require further investigations.
authors.affiliation: Department of Medical Oncology, Hôpital Pitié Salpêtrière, Paris, France.
authors.forename: E C
authors.initials: EC
authors.lastname: Antoine
authors.forename: O
authors.initials: O
authors.lastname: Rixe
authors.forename: E
authors.initials: E
authors.lastname: Vuillemin
authors.forename: A
authors.initials: A
authors.lastname: Benhammouda
authors.forename: C
authors.initials: C
authors.lastname: Borel
authors.forename: G C
authors.initials: GC
authors.lastname: Ghironzi
authors.forename: E
authors.initials: E
authors.lastname: Mularoni
authors.forename: C
authors.initials: C
authors.lastname: Franks
authors.forename: G
authors.initials: G
authors.lastname: Auclerc
authors.forename: C
authors.initials: C
authors.lastname: Soubrane
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary* / Q000628:therapy; D008875:Middle Aged; D011994:Recombinant Proteins; D013629:Tamoxifen / Q000008:administration & dosage
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D013629:Tamoxifen; D002945:Cisplatin